<DOC>
	<DOCNO>NCT00882180</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , pharmacokinetics , pharmacodynamics intravenous ALN-VSP02 , RNAi therapeutic , patient advance solid tumor liver involvement .</brief_summary>
	<brief_title>Dose Escalation Trial Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics Intravenous ALN-VSP02 In Patients With Advanced Solid Tumors With Liver Involvement</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients must histologically cytologically confirm advanced solid tumor recur progress follow standard therapy , respond standard therapy , standard therapy , candidate standard therapy Patient measurable tumor liver At least 28 day elapse since patient 's prior systemic therapy , radiotherapy , major surgery Patient Eastern Cooperative Oncology Group ( ECOG ) performance status score 01 Patient adequate hematologic , liver , renal function Patient seronegative hepatitis B virus ( HBV ) hepatitis C virus ( HCV ) Patient life expectancy &gt; 12 week Patient receive fulldose ( therapeutic ) anticoagulation therapy and/or aspirin &gt; 325 mg/day platelet inhibitory agent Patient clinically significant cardiovascular disease uncontrolled serious cardiac arrythmia Patient know active brain leptomeningeal metastases Patient clinically significant cerebrovascular disease Patient seizure disorder control medication Patient know suspected viral , parasitic fungal infection Patient previously experience severe reaction liposomal product Patient know hypersensitivity lipid product</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Liver</keyword>
	<keyword>Solid Tumors</keyword>
	<keyword>Advanced Solid Tumors Liver Involvement</keyword>
</DOC>